Welcome to our dedicated page for CS Diagnostics news (Ticker: CSDX), a resource for investors and traders seeking the latest updates and insights on CS Diagnostics stock.
CS Diagnostics Corp. (CSDX) develops medical technology and hygiene solutions through a portfolio that includes MEDUSA, a disinfectant and hygiene platform for wet wipes and liquid formulations, and CS-Protect Hydrogel, an organ spacer medical device designed to protect healthy organs during prostate cancer radiotherapy. Company updates commonly cover product commercialization, manufacturing arrangements, distribution channels, patent and regulatory activity, and international expansion across the United States, the GCC region and Europe.
News also reflects CSDX's public-company reporting and capital-structure activity, including auditor engagement, consolidated financial reporting work for affiliated entities, Regulation D financing, and the completed conversion of Series B Preferred Stock held by affiliates into common stock.
CS Group (OTCQB: CSDX) appointed Shah Teelani & Associates, a Dubai-based PCAOB-registered audit firm, to consolidate and audit the Group's 2025 financial statements for CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH.
The engagement aims to strengthen financial governance, align reporting with U.S. public company standards, improve transparency, and support international expansion across the U.S., GCC and Europe.
CS Diagnostics (OTCQB: CSDX) confirmed strategic manufacturing agreements to scale commercial production of MEDUSA SDP wet wipes and liquid disinfectants ahead of a planned global launch.
Emirate Wet Wipes LLC will manufacture MEDUSA SDP disinfectant wipes; Gulf Centre Group Factory will produce bulk liquid formulations in 500ml and 5-liter formats, supporting hospital, clinic, retail, and e-commerce distribution.
CS Group (OTCQB: CSDX) outlined a multi-channel sales model, global logistics partners, and a sustainability roadmap to support commercial rollout of MEDUSA SDP on Jan 21, 2026. Distribution will target institutional B2B channels—hospitals, gyms, schools, corporate clients—and B2C routes including physical retail in UAE and Germany, major online marketplaces, and direct-to-consumer e-commerce. DHL is appointed for bulk/institutional shipments and FedEx for retail and consumer deliveries. The company plans to begin regulatory approval processes for a bio-degradable, dissolving MEDUSA SDP wet wipes line as part of its sustainability roadmap, positioning the product for global fulfillment and future market expansion.
CS Diagnostics Corp (OTCQB:CSDX) announced that affiliates CS Interpharm and CS Diagnostics Pharma have completed conversion of their Series B preferred shares into unrestricted common stock. The conversion supports the company's plan to prepare consolidated financial statements by fiscal year-end, December 31, 2025, and to simplify equity structure by eliminating preferred dividend tracking.
Management says the move will increase transparency, streamline administration, improve alignment among affiliates, and strengthen CSDX's position for capital-market access and potential uplisting.
CS Diagnostics Corp. (OTCQB:CSDX) launched a Regulation D, Rule 506(c) offering on October 13, 2025, selling CSDX Preferred C Shares to U.S. accredited and non-U.S. investors to fund commercialization of CS Protect Hydrogel and MEDUSA.
Net proceeds are planned to be allocated roughly: Regulatory 20–25%, Manufacturing 15–20%, Sales & Marketing 20–25%, R&D 10–15%, Working capital 10–15%, and Token/platform support 5–10%. Offering documents (PPM, Subscription Agreement) are available on the company website.
CS Diagnostics Corp. (OTCQB: CSDX) announced significant progress across multiple fronts, including regulatory advancements for its flagship products and strong financial growth. The company's CS-Protect Hydrogel is under FDA review and has initiated patent filings in multiple countries. Their protective solution MEDUSA has secured authorization in the UAE and Europe, with EPA review ongoing in the US.
CSI, their subsidiary, reported a 75% increase in turnover for 2025 compared to 2024's $3.5 million. CSDX is launching a Regulation D offering and plans to become fully SEC-reporting by end of September 2025. The company is preparing for European market entry with MEDUSA shipments scheduled for October 2025.
CS Diagnostics Corp. (OTCQB:CSDX) has submitted a patent application for its CS-Protect Hydrogel technology, marking a significant milestone in its FDA application process. The company has partnered with Paul & Albrecht Patentanwälte, a prestigious German intellectual property law firm, to protect its innovative organ spacer medical device.
CS-Protect Hydrogel stands out for its versatility in treating various pathologies, featuring advanced molecular structure and chemical physical properties. The partnership with Paul & Albrecht, established in 1977, aims to ensure robust international intellectual property protection for CS Diagnostics' innovations.
CS Diagnostics Corp. (OTCQB:CSDX) has submitted its final Form F-10 registration statement draft to the Processing Team for Edgardization and subsequent filing with the SEC. This regulatory filing represents a strategic move towards enhancing market presence and transparency.
Company executives highlighted the significance of this filing, with Board President Thomas Fahrhoefer emphasizing its alignment with market regulatory standards, while Vice President Mohammad EsSayed noted it as a foundational step in the company's journey toward a potential Nasdaq listing.
CS Group (CSDX) has announced that its subsidiary CS Interpharm General Trading CO. LLC has signed a Memorandum of Understanding (MOU) and Non-Disclosure Agreement (NDA) with Gulf Center Group, a UAE-based manufacturer of plastic packaging and hygiene-related chemicals.
Under the agreement, Gulf Center Group will provide exclusive end-to-end manufacturing support for CS Group's MEDUSA product line, including customized bottle design, filling, and production services. The collaboration aims to align with MEDUSA brand's identity and quality standards.
According to company executives, this partnership represents a strategic move to enhance the product line and secure reliable manufacturing support while strengthening supply chain capabilities in the UAE region.